Illustration of the morphology of coronaviruses; the club-shaped viral spike peplomers, coloured red, create the look of a corona surrounding the virion, when observed with an electron microscope
Illustration of the morphology of coronaviruses; the club-shaped viral spike peplomers, coloured red, create the look of a corona surrounding the virion, when observed with an electron microscope
Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China
The virus that causes COVID-19 probably emerged from an animal source, but is now spreading from person to person. The virus is thought to spread mainly between people who are in close contact with one another (within about 6 feet) through respiratory droplets produced when an infected person coughs or sneezes. It also may be possible that a person can get COVID-19 by touching a surface or object that has the virus on it and then touching their own mouth, nose, or possibly their eyes, but this is not thought to be the main way the virus spreads.Learn what is known about the spread of newly emerged coronaviruses at https://www.cdc.gov/coronavirus/2019-ncov/about/transmission.html
Patients with COVID-19 have had mild to severe respiratory illness with symptoms of:
  • Fever
  • Cough
  • Shortness of breath
  • Avoid close contact with people who are sick
  • Avoid touching your eyes, nose, and mouth with unwashed hands
  • Wash your hands often with soap and water for at least 20 seconds. Use an alcohol-based hand sanitizer that contains at least 60% alcohol if soap and water are not available
The virus that causes COVID-19 probably emerged from an animal source, but is now spreading from person to person. The virus is thought to spread mainly between people who are in close contact with one another (within about 6 feet) through respiratory droplets produced when an infected person coughs or sneezes. It also may be possible that a person can get COVID-19 by touching a surface or object that has the virus on it and then touching their own mouth, nose, or possibly their eyes, but this is not thought to be the main way the virus spreads.Learn what is known about the spread of newly emerged coronaviruses at https://www.cdc.gov/coronavirus/2019-ncov/about/transmission.html.
  • Stay home when you are sick
  • Cover your cough or sneeze with a tissue, then throw the tissue in the trash
  • Clean and disinfect frequently touched objects and surfaces
S. No. Name of State / UT Total Confirmed Cases Cured/Discharged/Migrated Death
1 Andaman and Nicobar Islands 45 35 0
2 Andhra Pradesh 7961 3917 96
3 Bihar 7181 5098 50
4 Chandigarh 381 315 6
5 Chhattisgarh 2028 1331 10
6 Delhi 53116 23569 2035
7 Goa 725 118 0
8 Gujarat 26141 18159 1618
9 Haryana 9743 4889 144
10 Himachal Pradesh 619 388 8
11 Jammu and Kashmir 5680 3194 75
12 Karnataka 8281 5210 124
13 Kerala 2912 1511 21
14 Ladakh 744 95 1
15 Madhya Pradesh 11582 8748 495
16 Maharashtra 124331 62773 5893
17 Manipur 681 218 0
18 Mizoram 130 1 0
19 Odisha 4677 3297 11
20 Puducherry 286 118 7
21 Punjab 3832 2636 92
22 Rajasthan 14156 10997 333
23 Tamil Nadu 54449 30271 666
24 Telangana 6526 3353 198
25 Uttarakhand 2177 1433 26
26 Uttar Pradesh 15785 9638 488
27 West Bengal 13090 7303 529
Total number of confirmed cases in India 395048 213831 12948
The information displayed above is as per data published by Ministry of Health & Family Welfare on 21 th June 2020 at 2:00 AM
Helpline Number Toll free: 1075 & +91-11-23978046

Glenmark launches Covid drug after DCGI nod; MRP at Rs 103 per tablet

Glenmark Pharmaceutical on Saturday said it has launched antiviral drug FAVIPIRAVIR, under the brand name FabiFlu , for the treatment of patient with the mind and moderated COVID-19 at a price of Rs. 103 per table.The drug will be available as a 200 mg tablet at a maximum retail price of Rs 3,500 for a strip of 34 tablet , Glenmark Pharmaceutical said. The Mumbai-based firm had on Friday received the manufacturing and marketing approval from the Drugs Controller General of India (DCGI).”This approval comes at a time when cases in India are spiralling like never before, putting a tremendous pressure on our healthcare system,” Glenmark Pharmaceuticals Chairman and MD Glenn Saldanha said.The company hopes that the availability of an effective treatment such as FabiFlu will considerably help assuage this pressure, and offer patients in India a much needed and timely therapy option, he added. Glenmark will work closely with the government and medical community to make FabiFlu quickly accessible to patients across the country, Saldanha noted.The tablets are being produced by the company at its Baddi facility in Himachal Pradesh. The drug will be available both through hospitals and the retail channel, Glenmark said.

Glenmark_corona_virus_tablet
Glenmark_corona_virus_tablet
Glenmark Pharmaceutical has launched antiviral drug FAVIPIRAVIR under the brand name FabiFlu